Bill Andrews, Ph.D.
Co-Founder, Chief Scientific Officer
With an illustrious career in biotech spanning over 28 years, Dr Andrews has spent the past 16 years researching ways to extend the human lifespan by telomere shortening in human cells.
Since graduating in 1981 with a Ph.D. in Molecular and Population Genetics from the University of Georgia, Dr Andrews went on to become one of the first to discover the RNA and protein components of human telomerase, for which he was awarded “National Inventor of the Year” in 1997.
He has worked for a number of prestigious corporations including Armos, Codon and Geron and EOS Biosciences. He is the founder, President and current CEO of Sierra Sciences in Reno, Nevada.
David W. Scott, Ph.D.
David W. Scott, Ph.D. is Professor of Immunology in the Department of Medicine at the Uniformed Services School of Health Sciences, Bethesda, MD, since 2010. An alumnus of Antioch College, University of Chicago and Yale, and a post-doc at Oxford, England, he held tenured faculty positions at Duke, University of Rochester, and the U. Maryland
Medical School. Dr. Scott has contributed to over 200 research papers on several subjects on immunologic tolerance, and its application in hemophilia, autoimmunity and allergy.
He is the author of two textbooks and recipient of a number of awards from the AAI, a Boerhaave Professorship at Leiden University, the National Hemophilia Foundation and a Scientific Achievement Award from AAPS.
Federico Gaeta, Ph.D.
Dr. Federico Gaeta has a distinguished career in drug discovery and development spanning four decades. He served as Senior Scientist and Principal Scientist at Bristol Myers Squibb and Merck (formerly Schering Plough), leading drug discovery research in Anti-infectives, Central Nervous System and Cardiovascular diseases. As Director of Chemistry at Cytel Corporation he pioneered work in Glycotechnology, Chemoenzymatic Carbohydrate Synthesis and Immunology. As Scientific Director and Telomerase Program Director at Geron Corporation, Dr. Gaeta identified the first potent, small molecule, inhibitors of human telomerase. He is the sole inventor of universal therapeutic cancer vaccine technologies based on telomerase. In collaboration with Sierra Sciences Dr. Gaeta invented the most potent activators of human telomerase known to date. Currently, he is a consultant for various biotechnology companies. Dr. Gaeta is named inventor in 102 Patents and Applications, and author of 49 publications in major, peer-reviewed, scientific journals.
Jeff Mathis, OTD, CHT, Ph.D
Co-Founder, Chief Executive Officer
Dr. Jeff Mathis is the President of Libella Gene Therapeutics.He employs over 190 professional staff in two states through his private practice with a focus on genetic testing and specialized therapies.
Dr. Mathis formed Libella in 2017 with the sole goal of completing a regulatory-approved Phase 1 human trial using AAV/hTERT to treat or significantly improve the condition of Alzheimer’s disease.
Lancer received his B.S. and M.S. degrees in Biotechnology in 2003 from the University of Nevada and has been working with Dr. Bill Andrews at Sierra Sciences since 2002. Lancer is an expert in the fields of molecular biology and qPCR, developing high-throughput assays, screening and developing compounds for telomerase activation, and engineering gene therapies to be used in the treatment of aging-related diseases. He specializes in the science of telomere-based technology.
Dr. Kaufmann began her academic career in the field of cellular biology, earning a Master’s Degree from the University of Connecticut in Tropical Ecology and Plant Physiology. Turning to medicine, she received her medical Degree at the University of Maryland, and completed a residency and fellowship at Johns Hopkins in the field of pediatric anesthesiology. For the last seven years she has been the Chief of Pediatric Anesthesia at the Joe DiMaggio Children’s Hospital, a nationally recognized center of excellence.
Her avid interest in the science of anti-aging begun many years ago as an intense hobby. Utilizing her knowledge in cell biology, human pharmacology and physiology, this hobby has now become a main focus. The Kaufmann Protocol represents years of non-clinical research leading to the first ever, comprehensive theory of aging, complete with an explanation of why we age and the tools to decelerate the process.
Dr Kaufmann has lectured at Raad Fest, People Unlimited, The Church of Perpetual Life and can been heard on talk radio as well as innumerable podcasts.